Skip to main content

Table 2 SABA prescriptions in the 12 months before the study visit

From: Over-prescription of short-acting β2-agonists remains a serious health concern in Kenya: results from the SABINA III study

SABA prescriptions 12 months before the study visit

All

(N = 405)

Primary care (n = 222)

Specialist care (n = 183)

Mild asthma (n = 208)

Moderate-to-severe asthma (n = 14)

All

(n = 222)

Mild asthma (n = 100)

Moderate-to-severe asthma (n = 83)

All

(n = 183)

Patients prescribed SABA monotherapy

 Yes

62 (15.3)

39 (18.8)

0 (0)

39 (17.6)

23 (23)

0 (0)

23 (12.6)

 No

343 (84.7)

169 (81.2)

14 (100)

183 (82.4)

77 (77)

83 (100)

160 (87.4)

Number of canisters/inhalers prescribed per patient 12 months before the study visit

 Mean (SD)

7.6 (4.0)

7.9 (4.3)

NA

7.9 (4.3)

6.9 (3.2)

NA

6.9 (3.2)

 Median (min, max)

6.0 (1.0, 14.0)

10.0 (1.0, 14.0)

NA

10.0 (1.0, 14.0)

6.0 (2.0, 12.0)

NA

6.0 (2.0, 12.0)

Number of prescriptions 12 months before the study visit (canisters/inhalers) by category

 1–2

9 (14.5)

8 (20.5)

NA

8 (20.5)

1 (4.3)

NA

1 (4.3)

 3–5

10 (16.1)

5 (12.8)

NA

5 (12.8)

5 (21.7)

NA

5 (21.7)

 6–9

16 (25.8)

5 (12.8)

NA

5 (12.8)

11 (47.8)

NA

11 (47.8)

 10–12

26 (41.9)

20 (51.3)

NA

20 (51.3)

6 (26.1)

NA

6 (26.1)

 ≥ 13

1 (1.6)

1 (2.6)

NA

1 (2.6)

0 (0)

NA

0 (0)

 Total

62

39

NA

39

23

NA

23

Patients prescribed SABA in addition to maintenance therapy

 Yes

294 (72.6)

162 (77.9)

12 (85.7)

174 (78.4)

65 (65)

55 (66.3)

120 (65.6)

 No

111 (27.4)

46 (22.1)

2 (14.3)

48 (21.6)

35 (35)

28 (33.7)

63 (34.4)

Number of canisters/inhalers prescribed per patient 12 months before the study visit

 Mean (SD)

7.3 (4.3)

7.5 (3.9)

8.0 (3.8)

7.6 (3.9)

7.6 (4.1)

6.1 (5.5)

6.9 (4.9)

 Median (min, max)

6.0 (1.0, 30.0)

6.0 (1.0, 14.0)

8.0 (1.0, 12.0)

6.0 (1.0, 14.0)

7.0 (1.0, 14.0)

4.0 (1.0, 30.0)

6.0 (1.0, 30.0)

Number of prescriptions 12 months before the study visit (canisters/inhalers) by category

 1–2

56 (19)

22 (13.6)

1 (8.3)

23 (13.2)

13 (20)

20 (36.4)

33 (27.5)

 3–5

47 (16)

30 (18.5)

2 (16.7)

32 (18.4)

7 (10.8)

8 (14.5)

15 (12.5)

 6–9

77 (26.2)

47 (29)

3 (25)

50 (28.7)

16 (24.6)

11 (20)

27 (22.5)

 10–12

108 (36.7)

61 (37.7)

6 (50)

67 (38.5)

28 (43.1)

13 (23.6)

41 (34.2)

 ≥ 13

6 (2)

2 (1.2)

0 (0)

2 (1.1)

1 (1.5)

3 (5.5)

4 (3.3)

 Total

294

162

12

174

65

55

120

  1. All data are described as n (%) unless otherwise specified
  2. max Maximum, min Minimum, NA Not applicable, SABA Short-acting β2-agonist, SD Standard deviation